Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 18, 2005

View Archived Issues

Rylomine induces analgesic effects in patients with postsurgical orthopedic pain

Celldex Therapeutics acquires Lorantis and assets of Alteris Therapeutics

OGX-011 begins new phase II study in prostate cancer

GPI-0100 adjuvant licensed by Hawaii Biotech

Osiris to begin phase II study of Prochymal for severe GVHD

Arrowhead Research accelerates investment in Insert Therapeutics

Trexima NDA accepted for review

IND filing for MEDI-545 for lupus

RTA-401 cleared for clinical testing

KP-1461 begins phase Ib study for HIV

Talabostat begins phase III for metastatic NSCLC

CHIR-12.12 enters phase I study for multiple myeloma

Inspire completes studies prior to end-of-phase II meeting

Mack and Transport enter agreement for cold sores device/drug product

Aerie closes Series A financing

Phase III program under way for Memryte implant

Benefits of rHuPH20 for cerebral brain ischemia and enhanced pharmacokinetics

M-475271 antitumor effects via inhibition of angiogenesis

Targeting CIDS for CNS injury: a new avenue for therapeutic investigation

New PDE inhibitors disclosed by Altana

Janssen patent claims new opioid receptor agonists for pain

Novel anti-HIV agents reported in recent patent literature

LY-456236 produces anticonvulsant effects in preclinical testing

New data on the metabolic effects of orexin A

Oral insulin prevents postprandial glucose excursions in patients with type 1 diabetes

Pioglitazone improves cardiovascular outcome in patients with type 2 diabetes

Update on the antibacterial efficacy of tigecycline

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
Muscarinic M4 receptor positive allosteric modulators described in Neurosterix patent
BioWorld Science
Neurosterix Pharma Sarl has divulged 3-cyclopropylpyrazole derivatives acting as muscarinic M4 receptor positive allosteric modulators. They are reported to be...